Poster Session B
Tuesday, January 10
12:15 p.m.-2:30 p.m.
In alphabetical order, not board assignment order
- A comprehensive non-coding RNA map in lung, liver and breast cancer uncovers novel players in tumorigenesis. Maria Polycarpou-Schwarz, Sebastian Aulmann, Thomas Longerich, Joachim Rom, Thomas Muley, Michael Meister, Heike Zabeck, Peter Sinn, Philipp A Schnabel, Hans Hoffmann, Peter Schirmacher, Tony Gutschner, Sven Diederichs, Stefanie Grund, Monika Hämmerle, An
- Automated multiplex assay for diagnostic application of contextual microRNA signatures in breast cancer. Wendy Wells, Sung-hee Choi, Gary Schwartz, Lorenzo F Sempere.
- Breast cancer progression suppressor miR-290 targets breast cancer biomarker Arid4b. Natalie Goldberger, Renard Walker, Chang Hee Kim, Kent Hunter.
- Characterization of a novel pseudogene expressed antisense RNA that regulates PTEN expression. Per Johnsson, Amanda Ackley, Dan Grandér, Kevin V Morris.
- Critical early microRNA-mediated signalling events during ATRA induced neuroblastoma cell differentiation. Niamh H Foley, Isabella M Bray, Raquel Fernandez, Raymond L Stallings.
- Expression of microRNAs-135b and -196b in response to cellular stress in leukemia cells. Tsui-Ting Ho, Xiaolong He, Ahmet Dirim Arslan, William T Beck.
- Genome-wide profiling reveals hyper- and hypomethylation at microRNA promoters in chronic lymphocytic leukemia. Constance Baer, Michael Rehli, John C. Byrd, Clemens-Martin Wendtner, Christoph Plass, Rainer Claus, Lukas Frenzel, Manuela Zucknick, Yoon Jung Park, Lei Gu, Dieter Weichenhan, Martina Fischer, Christian Pallasch.
- Human genome contains a large number of very long intergenic transcribed regions, some of which are associated with cancer outcome. Anirban P Mitra, Timothy J Triche, Sheetal A Mitra, Jonathan D Buckley, Poul H. B. Sorensen, C Patrick Reynolds, Robert J Arceci, Patrice Milos, Georges St. Laurent, Philipp Kapranov.
- Inhibition of lung tumor progression in a metastatic mouse model following intravenous delivery of siRNA nanocomplexes. Jason G Fewell, Khursheed Anwer, Kevin Polach, Majed Matar, Jennifer Rice, Angela Rea-Ramsey, Jeff Sparks, Diane McClure, Casey Pence, Elaine Brunhoeber, Leslie Wilkinson.
- microRNA regulation of cell viability and drug sensitivity in lung cancer. Liqin Du, Christopher DeSevo, Borkowski Robert, Baker Michael, Adi F Gazdar, John D Minna, Alexander Pertsemlidis.
- microRNA-181a regulates ovarian cancer progression and is associated with poor outcome in late-stage epithelial ovarian cancer. Aditya Parikh, Analisa DiFeo, Christine Lee, Alessia Baccarini, Valentin Kolev, Jamal Rahaman, Peter Dottino, Tamara Kalir, Brian D Brown, Goutham Narla.
- microRNA-424 as a potential regulator of mammary cell epithelial-to-mesenchymal transition and breast cancer stem-like cell properties. David J Drasin, Deepika Neelakantan, Heide L Ford.
- microRNA-641 activates MAPK by targeting NF1 and cooperates with its host gene AKT2 in human cancer. Edward J Richards, Marc Coppola, Jianping Guo, William Kong, Jin Q Cheng.
- microRNAs differentially expressed in preoperative human serum of ovarian cancer. Angel Chao, Tzu Hao Wang, Hua-Chien Chen, Shu-Jen Chen, Chyong-Huey Lai.
- miR-34c is a putative tumor suppressor microRNA in Dicer-Pten double knockout high grade-serous carcinomas. Zhifeng Yu, Jaeyeon Kim, Chad Creighton, Shannon Hawkins, Martin Matthew Matzuk.
- Molecular function of the RNA binding protein EWS in RNA processing. Bethsaida I Nieves, Shuang Niu, Dedeepya Vaka, Julia Salzman, Patrick Brown, E. Alejandro Sweet-Cordero.
- New views on microRNAs involvement in melanoma. Eyal Greenberg, Eran Eyal, Gideon Rechavi, Noam Shomron, Jacob Schachter, Gal Markel, Yael Nemlich, Steven Hajdu, Orit Itzhaki, Liat Edry, Oz Solomon, Ninette Amariglio, Michal J Besser, Yona Keisari.
- Repression of PDGFRA-targeting miR-34a promotes tumorigenesis in proneural malignant gliomas. Joachim Silber, Anders Jacobsen, Tatsuya Ozawa, Girish Harinath, Eric C Holland, Chris Sander, Jason T Huse.
- Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Ivan Garcia-Bassets.
- Selective inhibition of a long non-coding RNA (lncRNA), MALAT1 by antisense oligonucleotides results in significant anti-tumor effects in a variety of preclinical cancer models. Jeff Hsu, Guobin He, Gourab Bhattacharjee, Tianyuan Zhou, Chris May, Xiaokun Xiao, Gene Hung, Brett P. Monia, A. Robert MacLeod, Youngsoo Kim.
- The microRNA signature characterizing neuroblastoma cancer stem cells collectively targets the p53 pathway. Danielle Hsu, Ashley Benham, Zaowen Zaowen , Cristian Coarfa, Eugene Kim, Preethi Gunaratne, Jason M Shohet.
- The miR-15 family and miR-155 mediate WEE1 and CHEK1 effects on cisplatin-resistance in cancer cells. Lynn M Pouliot, Jennifer Bai, Matthew D Hall, Scott E. Martin , Michael M. Gottesman.
- The paralogous microRNA clusters, miR-17-92 and miR-106-25, are specifically overexpressed in metastatic non-small cell lung carcinomas. Katey SS Enfield, Stephen Lam, Wan L Lam.
- The transcribed non-coding genome modulates the biology of Ewing sarcoma family of tumors. Sheetal A Mitra, Daniel H Wai, William A May, Jonathan D Buckley, Philipp Kapranov, Robert J Arceci, Timothy J Triche.
- Treatment of ovarian cancer with targeted tumor-penetrating siRNA nanocomplexes. Yin Ren, Hiu Wing Cheung, Ronny Drapkin, David Root, Justin Lo, Valentina Fogal, Erkki Ruoslahti, William Hahn, Sangeeta Bhatia, Geoffrey von Maltzahn, Amit Agrawal, Glenn Cowley, Barbara Weir, Jesse Boehm, Pablo Tamayo, Jill Mesirov, Alison Karst.